{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T04:35:42Z","timestamp":1741754142710,"version":"3.38.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clgc.2024.102290","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:42:20Z","timestamp":1733848940000},"page":"102290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility and Oncological Outcome of Patients Achieving Noninvasive Downstaging After Transurethral Resection of Bladder Tumor Plus Systemic Chemotherapy for Bladder Preservation Strategy in Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1568-1120","authenticated-orcid":false,"given":"Takehisa","family":"Onishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Shibahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Sekito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2024.102290_bib0001","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU Guidelines on muscle-invasive and metastatic bladder cancer","volume":"71","author":"Witjes","year":"2017","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102290_bib0002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.eururo.2018.09.047","article-title":"Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial","volume":"75","author":"Gschwend","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102290_bib0003","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.21037\/tau.2020.02.10","article-title":"Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer","volume":"9","author":"Tholomier","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102290_bib0004","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102290_bib0005","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102290_bib0006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Witjes","year":"2024","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102290_bib0007","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1200\/JOP.2017.024919","article-title":"Treatment of nonmetastatic muscle-invasive bladder cancer: American urological association\/American society of clinical oncology\/American society for radiation oncology\/Society of urologic oncology clinical practice guideline summary","volume":"13","author":"Chang","year":"2017","journal-title":"J Oncol Pract"},{"issue":"4","key":"10.1016\/j.clgc.2024.102290_bib0008","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.clgc.2024.102290_bib0009","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eururo.2007.12.031","article-title":"Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102290_bib0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.urology.2017.09.003","article-title":"Outcomes following clinical complete response to neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder in patients refusing radical cystectomy","volume":"111","author":"Robins","year":"2018","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.clgc.2024.102290_bib0011","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: Contemporary outcomes of a multi-institutional cohort study","volume":"200","author":"Mazza","year":"2018","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102290_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2020.07.016","article-title":"Impact of noninvasive down-staging after transurethral resection of bladder tumor plus systemic chemotherapy on bladder-sparing strategy in patients with muscle-invasive bladder cancer","volume":"39","author":"Onishi","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2024.102290_bib0013","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clgc.2024.102290_bib0014","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/cancers16071292","article-title":"Non-surgical bladder-sparing multimodal management in organ-confoned urothelial carcinoma of the urinary bladder: a population-based analysis","volume":"16","author":"Angelis","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.clgc.2024.102290_bib0015","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.euf.2016.12.005","article-title":"Absence of tumor on repeat transurethral resection of bladder tumor does not predict final pathologic T0 stage in bladder cancer treated with radical cystectomy","volume":"4","author":"Kukreja","year":"2018","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.clgc.2024.102290_bib0016","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2020.07.016","article-title":"Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"79","author":"Becker","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102290_bib0017","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00345-021-03839-7","article-title":"Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients","volume":"40","author":"van Hoogstraten","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2024.102290_bib0018","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urology.2020.03.021","article-title":"Occult nodal metastases in patients down-staged to nonmuscle invasive disease following neoadjuvant chemotherapy","volume":"142","author":"Nassiri","year":"2020","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.clgc.2024.102290_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.10.021","article-title":"Impact of adequate pelvic lymph node dissection on overall survival after radical cystectomy: A stratified analysis by clinical stage and receipt of neoadjuvant chemotherapy","volume":"36","author":"von Landenberg","year":"2018","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102290_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2023.06.016","article-title":"The Role of lymph node dissection in patients with muscle-invasive bladder cancer who underwent radical cystectomy following neoadjuvant chemotherapy","volume":"22","author":"Zennami","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102290_bib0021","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bju.14736","article-title":"Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients","volume":"124","author":"Kijima","year":"2019","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.clgc.2024.102290_bib0022","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clgc.2014.01.005","article-title":"Role of maximal endoscopic resection before cystectomy for invasive urothelial bladder cancer","volume":"12","author":"James","year":"2014","journal-title":"Clin Genitourin Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400260X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732400260X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T12:36:06Z","timestamp":1741696566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732400260X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S155876732400260X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102290","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility and Oncological Outcome of Patients Achieving Noninvasive Downstaging After Transurethral Resection of Bladder Tumor Plus Systemic Chemotherapy for Bladder Preservation Strategy in Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102290"}}